VRAX Overview

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Wall Street analysts forecast VRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Virax Biolabs Group Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Virax Biolabs Group Ltd. EPS for the last quarter amounts to USD, decreased

Virax Biolabs Group Ltd (VRAX) has 19 emplpoyees as of May 30 2026.

Today VRAX has the market capitalization of 4.37M USD.